안구건조증 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the dry eye disease market size is expected to grow from USD 6.35 billion in 2025 to USD 6.61 billion in 2026 and is forecast to reach USD 8.03 billion by 2031 at 3.96% CAGR over 2026-2031.

This report is Segmented by Type (Treatment and Diagnostic Test), Disease Type (Evaporative, Aqueous-Deficient, Mixed Mechanism), Dosage Form (Eye Drops, Ointments & Gels, and More), Distribution Channel (Hospital, Independent, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Dry Eye Disease Market Trends and Insights

Rising Global Prevalence Of Dry Eye Disease Linked To Aging And Comorbidities

The world's 60-plus population is expected to double to 2.1 billion by 2050, expanding the at-risk cohort faster than current ophthalmic infrastructure can serve it. Diabetes and autoimmune disorders compound disease burden, with Sjogren's syndrome affecting 4 million United States adults and driving multi-modal treatment needs beyond artificial tears. Pharmaceutical companies now frame the condition as chronic inflammation rather than transient discomfort, aligning dry eye protocols with rheumatology and endocrinology pathways to secure higher reimbursement. This repositioning mirrors osteoarthritis's evolution, in which biologics displaced NSAIDs by treating the pathophysiology rather than pain alone. As a result, prescription uptake is climbing and will continue to reinforce the trajectory of the dry eye disease market size.

Escalating Screen-Time Across All Age Groups Increasing Ocular Surface Stress

Average daily digital use among United States adults climbed to 7 hours in 2025, up from 4 hours in 2019, embedding prolonged screen exposure as a structural reality for office workers. Pediatric usage now reaches 4-6 hours per day, raising early-onset cases. Employers observe productivity losses due to digital eye strain and are trialing vision wellness benefits that subsidize preservative-free drops. Ophthalmologists recommend "20-20-20" micro-breaks along with pharmacotherapy, spurring demand for single-dose vials that command 15-20% price premiums. This behavior-driven demand engine magnifies near-term growth in the dry eye disease market.

Generic Competition Compressing Prices Of Established Cyclosporine & Lubricant Brands

Wholesale acquisition costs for generic cyclosporine fell to USD 150 per 30-day supply versus USD 600 for branded Restasis, prompting mandatory substitution by payers. Private-label artificial tears now undercut leading brands by up to 50%, forcing innovators to justify premiums through preservative-free lipids or extended-release gels. The margin squeeze is most acute in the U.S. and Europe but is spreading to Asia as regulators clear local generics. Consequently, established players are redirecting R&D budgets into TRPM8 agonists and secretagogues that remain patent-protected beyond 2030.

Other drivers and restraints analyzed in the detailed report include:

1. Adoption Of Prescription Anti-inflammatory & Secretagogue Therapies Worldwide
2. Favorable Regulatory Pathways & Fast-Track Approvals For Novel Tear Modulators
3. Limited Long-Term Efficacy & Safety Data For Emerging Devices And Biologics

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Treatment modalities accounted for 42.35% of 2025 revenue in the dry eye disease market. Prescription anti-inflammatories and secretagogues are displacing OTC lubricants as moderate-to-severe cases seek durable relief. Newly launched agents acoltremon, perfluorohexyloctane, and high-strength cyclosporine added USD 300 million in first-year sales, confirming the pull toward mechanism-based interventions. At the same time, diagnostic revenues are rising because tear osmolarity and MMP-9 assays provide objective data that justify therapy escalation.

Diagnostic uptake feeds treatment volumes. Point-of-care devices compress multi-visit workflows into single encounters, enhancing patient conversion. CPT reimbursement for osmolarity testing incentivizes optometrists to adopt these tools, broadening access outside hospital ophthalmology departments. As a result, diagnostics act as a force multiplier for prescription drug lines, bolstering overall growth in the dry eye disease market.

Evaporative subtypes captured 52.40% of 2025 revenue, reflecting widespread meibomian dysfunction. Nevertheless, aqueous-deficient cases are projected to have the fastest trajectory, with a 7.45% CAGR, as Sjogren's diagnoses increase and post-LASIK cohorts age. Secretagogues such as acoltremon specifically address tear-volume deficits, creating fresh revenue streams.

Mixed-mechanism presentations are rising as clinicians deploy comprehensive diagnostics that reveal both lipid and aqueous deficiencies. Personalized combinations, pairing device-based gland treatments with secretagogues or immunomodulators, deliver superior outcomes and encourage diversified company portfolios. This nuanced approach positions multi-mechanism suppliers to capture incremental market share from single-pathway competitors in the dry eye disease market.

Complete Report Scope:

• By Type
  • Treatment
    • Artificial Tears
    • Prescription Drugs
      • Anti-inflammatory
      • Secretagogues
      • Other Prescription Therapies
    • Punctal Plugs
    • Others
  • Diagnostic Test
    • Schirmers Test
    • Corneal Staining
    • Tear Break-up Time (TBUT)
    • Optical Coherence Tomography (OCT)
    • Tear Film Stability Analysis
    • Tear Osmolarity
    • Others
• By Disease Type
  • Evaporative Dry Eye
  • Aqueous-deficient Dry Eye
  • Mixed Mechanism
• By Dosage Form
  • Eye Drops (Multi-dose & Single-dose PF)
  • Ointments & Gels
  • Ophthalmic Inserts & Nasal Sprays
• By Distribution Channel
  • Hospital Pharmacies
  • Independent Pharmacies & Drug Stores
  • Online Pharmacies & E-commerce Portals
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 35.42% of 2025 revenue, driven by high diagnosis rates, generous insurance coverage, and rapid uptake of newly approved mechanisms. The United States accounts for 80% of regional turnover, propelled by Medicare Part D coverage of cyclosporine and lifitegrast and by commercial formularies that increasingly reimburse novel secretagogues. Canada's growth is tempered by centralized purchasing but benefits from widespread awareness campaigns that encourage early diagnosis. Mexico lags due to lower per-capita spending, yet tele-ophthalmology is broadening access in urban hubs such as Monterrey and Guadalajara, sustaining steady gains in the dry eye disease market. Europe ranks second in revenue but trails in growth because price negotiations with each member state introduce launch delays and margin pressure. Germany's statutory health funds reimburse prescription agents with limited co-pays, making it the most significant European market.

Asia-Pacific is forecast to deliver a 7.28% CAGR through 2031, the highest globally. China's regulatory reforms narrow approval gaps with the West, enabling earlier entry of secretagogues while domestic cyclosporine generics capture price-sensitive segments. India struggles with affordability, but smartphone-based care platforms extend reach into tier-2 cities and enable bulk ordering of lubricants online. Japan and South Korea, with aging demographics and strong insurance coverage, are quickly adopting innovative treatments, providing attractive early-revenue opportunities. Australia's PBS subsidizes prescription agents, aligning its therapeutic landscape closely with that of North America. The Middle East and Africa remain nascent, though the United Arab Emirates and Saudi Arabia witness rising demand from air-conditioned urban lifestyles

1. Abbvie
2. Advanced Tear Diagnostics
3. AFT Pharmaceuticals
4. Alcon
5. Bausch Health
6. Carl Zeiss
7. Dompe Farmaceutici
8. Harrow Health (ImprimisRx)
9. Horus Pharma
10. Johnson & Johnson
11. Kala Pharmaceuticals
12. Novaliq
13. Novartis
14. OASIS Medical Inc.
15. Otsuka
16. Prestige Consumer Healthcare
17. Reckitt Benckiser (TheraTears)
18. Santen Pharmaceuticals
19. Scope Ophthalmics Ltd
20. Sentiss Pharma
21. Sun Pharmaceuticals Industries
22. TearLab Corporation
23. Tomey
24. Viatris Inc. (Oyster Point Pharma)
25. VISUfarma B.V.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Global Prevalence of Dry Eye Disease Linked to Aging and Comorbidities
  • 4.2.2 Escalating Screen-Time Across All Age Groups Increasing Ocular Surface Stress
  • 4.2.3 Adoption of Prescription Anti-inflammatory & Secretagogue Therapies Worldwide
  • 4.2.4 Favorable Regulatory Pathways & Fast-Track Approvals for Novel Tear Modulators
  • 4.2.5 Direct-to-Consumer Awareness Campaigns and Tele-ophthalmology Expanding Diagnosis Rates
  • 4.2.6 Growing Innovations in Treatment Options
• 4.3 Market Restraints
  • 4.3.1 Generic Competition Compressing Prices of Established Cyclosporine & Lubricant Brands
  • 4.3.2 Limited Long-term Efficacy & Safety Data for Emerging Devices and Biologics
  • 4.3.3 Inadequate Insurance Coverage and High Out-of-Pocket Costs in Developing Regions
  • 4.3.4 Chronic Dosing Burden Leading to Poor Patient Adherence & Sub-optimal Outcomes
• 4.4 Supply-Chain Analysis
• 4.5 Technological Outlook
• 4.6 Regulatory Landscape
• 4.7 Porters Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers/Consumers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Type
  • 5.1.1 Treatment
    • 5.1.1.1 Artificial Tears
    • 5.1.1.2 Prescription Drugs
      • 5.1.1.2.1 Anti-inflammatory
      • 5.1.1.2.2 Secretagogues
      • 5.1.1.2.3 Other Prescription Therapies
    • 5.1.1.3 Punctal Plugs
    • 5.1.1.4 Others
  • 5.1.2 Diagnostic Test
    • 5.1.2.1 Schirmers Test
    • 5.1.2.2 Corneal Staining
    • 5.1.2.3 Tear Break-up Time (TBUT)
    • 5.1.2.4 Optical Coherence Tomography (OCT)
    • 5.1.2.5 Tear Film Stability Analysis
    • 5.1.2.6 Tear Osmolarity
    • 5.1.2.7 Others
• 5.2 By Disease Type
  • 5.2.1 Evaporative Dry Eye
  • 5.2.2 Aqueous-deficient Dry Eye
  • 5.2.3 Mixed Mechanism
• 5.3 By Dosage Form
  • 5.3.1 Eye Drops (Multi-dose & Single-dose PF)
  • 5.3.2 Ointments & Gels
  • 5.3.3 Ophthalmic Inserts & Nasal Sprays
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Independent Pharmacies & Drug Stores
  • 5.4.3 Online Pharmacies & E-commerce Portals
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 AbbVie Inc. (Allergan)
  • 6.3.2 Advanced Tear Diagnostics
  • 6.3.3 AFT Pharmaceuticals
  • 6.3.4 Alcon Inc.
  • 6.3.5 Bausch Health Companies Inc.
  • 6.3.6 Carl Zeiss Meditec AG
  • 6.3.7 Dompe Farmaceutici
  • 6.3.8 Harrow Health (ImprimisRx)
  • 6.3.9 Horus Pharma
  • 6.3.10 Johnson & Johnson Services, Inc.
  • 6.3.11 Kala Pharmaceuticals
  • 6.3.12 Novaliq GmbH
  • 6.3.13 Novartis AG
  • 6.3.14 OASIS Medical Inc.
  • 6.3.15 Otsuka Pharmaceutical Co. Ltd
  • 6.3.16 Prestige Consumer Healthcare
  • 6.3.17 Reckitt Benckiser (TheraTears)
  • 6.3.18 Santen Pharmaceutical Co. Ltd
  • 6.3.19 Scope Ophthalmics Ltd
  • 6.3.20 Sentiss Pharma Pvt. Ltd
  • 6.3.21 Sun Pharmaceutical Industries Ltd
  • 6.3.22 TearLab Corporation
  • 6.3.23 Tomey Corporation
  • 6.3.24 Viatris Inc. (Oyster Point Pharma)
  • 6.3.25 VISUfarma B.V.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment